Results 141 to 150 of about 1,927 (159)

Raltegravir resistance in the cerebrospinal fluid

Infection, 2013
We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase inhibitor resistance in the plasma of a patient without human immunodeficiency virus (HIV)-encephalitis in the context of other HIV-associated central nervous system infections.
Bruce J. Brew, Borja Mora-Peris, Alan Winston, Nicola Mackie, David A. Cooper, Dan Suan   +5 more
openaire   +3 more sources

Treatment of HIV infection with raltegravir

Expert Opinion on Pharmacotherapy, 2009
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus.To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability.Data from pharmacokinetic, Phase II and III clinical trials were reviewed ...
Lisa M. Chirch, Roy T. Steigbigel, Sidonie A. Morrison   +2 more
openaire   +3 more sources

Effect of Raltegravir on the Total and Unintegrated Proviral HIV Dna during Raltegravir-Based Haart

Antiviral Therapy, 2011
Background Raltegravir is the first approved antiretroviral able to prevent HIV genome integration into the host chromosomes. The aim of the study is to test if raltegravir plasma concentrations can be associated with proviral DNA decline during raltegravir-based salvage therapy.
E. Nicastri, C. Tommasi, I. Abbate, BONORA, Stefano, M. Tempestilli, R. Bellagamba, M. Viscione, G. Rozera, A. L. Gallo, J. Ivanovic, A. Amendola, L. Pucillo, DI PERRI, Giovanni, M. R. Capobianchi, P. Narciso   +14 more
openaire   +3 more sources

Raltegravir as antiretroviral therapy in HIV/AIDS

Expert Opinion on Pharmacotherapy, 2013
HIV, a major cause of morbidity and mortality worldwide has been transformed by antiretroviral (ARV) therapy into a manageable condition. Drug resistance, tolerability and drug interactions remain major concerns when choosing ARV therapy. Raltegravir , the first integrase inhibitor in the armamentarium against HIV, has been shown to be efficacious in ...
Sharon Walmsley, Malika Sharma
openaire   +3 more sources

A safety evaluation of raltegravir for the treatment of HIV

Expert Opinion on Drug Safety, 2017
Raltegravir (RAL) was the first commercialized agent from a new drug class with an innovative target, the integrase. Since its introduction in clinical practice RAL has become widely used for the treatment of HIV-1 infected patients. A decade after its approval, this article reviews key evidence from RAL with a special interest on safety outcomes ...
Natalia Stella-Ascariz, Rocío Montejano, Jose R. Arribas, Rosa de Miguel   +3 more
openaire   +3 more sources

Role of Raltegravir in HIV-1 Management

Annals of Pharmacotherapy, 2012
Objective: To review the literature concerning the role of raltegravir in the treatment of HIV-1 in antiretroviral (ARV)-experienced and ARV-naïve patients. Data Sources: A PubMed search was conducted for published data through March 2012 using the search terms raltegravir, MK-0518, and integrase strand transfer inhibitor.
Rokas, Kristina E, Bookstaver, P Brandon, Shamroe, Caitlin L, Sutton, S Scott, Millisor, Vanessa E, Bryant, Jacquelyn E, Weissman, Sharon B   +6 more
openaire   +3 more sources

Pharmacokinetics of Raltegravir in the Semen of HIV-Infectedmen [PDF]

Antiviral Therapy, 2013
Background We sought to determine the pharmacokinetic disposition of raltegravir in the blood and seminal plasma of HIV-infected men. Methods We conducted a pharmacokinetic study using a staggered sampling approach. A total of 16 HIV-infected men receiving raltegravir-based therapy were recruited into the study.
Charles la Porte, Graham C. Smith, Jason Brunetta, Roberta Halpenny, Mona Loutfy, Tony Antoniou   +5 more
openaire   +2 more sources

Pharmacokinetic and safety of raltegravir in pregnancy

European Journal of Clinical Pharmacology, 2012
Dear Sirs:The aim of anti-HIV treatment in pregnancy is the suppres-sion of the HIV-1 RNA viral load in the plasma beforedelivery [1] to prevent mother-to-child transmission of theinfection. The achievement of this outcome may be compli-cated in pregnant women who have been treated with mul-tiple drugs by the lack of active drugs available ...
Maria Piera Riccardi, Tiziana Carli, Barbara Ricciardi, Cesira Nencioni, Mario Toti, Maria Pia Allegri, Silvia Chigiotti, Michele Trezzi, Leonardo Croci   +8 more
openaire   +2 more sources

Raltegravir in patients with tuberculosis

The Lancet Infectious Diseases, 2021
Anton Pozniak, Graeme Meintjes
openaire   +3 more sources

Raltegravir in pregnancy: a case series presentation

International Journal of STD & AIDS, 2011
Adequate antiretroviral therapy is essential for HIV-positive pregnant women to prevent mother-to-child transmission. We report a small case series of five women receiving raltegravir as part of their antiretroviral regimen during pregnancy.
V Touzeau, M Geit, Richard Greil, Naomi Taylor, Martin Gisinger, Armin Rieger, Alexander Egle, Robert Zangerle   +7 more
openaire   +3 more sources